Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies

Elena Bresin, Sara Gastoldi, Erica Daina, Daniela Belotti, Enrico Pogliani, Paolo Perseghin, Potito R. Scalzulli, Rossella Paolini, Raimondo Marcenò, Giuseppe Remuzzi, Miriam Galbusera

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Thrombotic thrombocytopenic purpura (TTP) is a rare and severe disease characterized by thrombocytopenia, microangiopathic haemolytic anemia, neurological and renal involvement associated with deficiency of the von Willebrand factor-cleaving protease, ADAMTS13. Persistence of high titers of anti-ADAMTS13 autoantibodies predisposes to relapsing TTP. Since relapses are associated with high morbidity and mortality rates, the optimal therapeutic option should be a pre-emptive treatment able to deplete anti-ADAMTS13 autoantibodies and avoid relapses. Five patients who presented with persistence of undetectable ADAMTS13 activity and high titers of autoantibodies, were treated with rituximab as pre-emptive therapy during remission. Four of them were affected by relapsing TTP and one was treated after the first episode. ADAMTS13 activity ranging from 15% to 75% with disappearance of inhibitors was achieved after three months in all patients, and persisted >20% without inhibitors at six months. In three patients disease-free status is still ongoing after 29, 24 and six months, respectively. Relapses were documented in two patients during follow-up: in one patient remission lasted 51 months; while in the other patient relapse occurred after 13 months. Results demonstrated that rituximab used as pre-emptive treatment may be effective in maintaining a sustained remission in patients with anti-ADAMTS13 antibodies in whom other treatments failed to limit the production of inhibitors, and suggests that re-treatment with rituximab should be considered when ADAMTS13 activity decreases and inhibitors reappear into the circulation, to avoid a new relapse.

Original languageEnglish
Pages (from-to)233-238
Number of pages6
JournalThrombosis and Haemostasis
Volume101
Issue number2
DOIs
Publication statusPublished - Feb 2009

Fingerprint

Thrombotic Thrombocytopenic Purpura
Autoantibodies
Recurrence
Therapeutics
Hemolytic Anemia
Rare Diseases
Rituximab
Thrombocytopenia
Anti-Idiotypic Antibodies
Morbidity
Kidney
Mortality

Keywords

  • ADAMTS13
  • Autoantibodies
  • Rare diseases
  • Rituximab
  • TTP

ASJC Scopus subject areas

  • Hematology

Cite this

Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies. / Bresin, Elena; Gastoldi, Sara; Daina, Erica; Belotti, Daniela; Pogliani, Enrico; Perseghin, Paolo; Scalzulli, Potito R.; Paolini, Rossella; Marcenò, Raimondo; Remuzzi, Giuseppe; Galbusera, Miriam.

In: Thrombosis and Haemostasis, Vol. 101, No. 2, 02.2009, p. 233-238.

Research output: Contribution to journalArticle

@article{fbfccad3dc6446e88331528c75ee185c,
title = "Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies",
abstract = "Thrombotic thrombocytopenic purpura (TTP) is a rare and severe disease characterized by thrombocytopenia, microangiopathic haemolytic anemia, neurological and renal involvement associated with deficiency of the von Willebrand factor-cleaving protease, ADAMTS13. Persistence of high titers of anti-ADAMTS13 autoantibodies predisposes to relapsing TTP. Since relapses are associated with high morbidity and mortality rates, the optimal therapeutic option should be a pre-emptive treatment able to deplete anti-ADAMTS13 autoantibodies and avoid relapses. Five patients who presented with persistence of undetectable ADAMTS13 activity and high titers of autoantibodies, were treated with rituximab as pre-emptive therapy during remission. Four of them were affected by relapsing TTP and one was treated after the first episode. ADAMTS13 activity ranging from 15{\%} to 75{\%} with disappearance of inhibitors was achieved after three months in all patients, and persisted >20{\%} without inhibitors at six months. In three patients disease-free status is still ongoing after 29, 24 and six months, respectively. Relapses were documented in two patients during follow-up: in one patient remission lasted 51 months; while in the other patient relapse occurred after 13 months. Results demonstrated that rituximab used as pre-emptive treatment may be effective in maintaining a sustained remission in patients with anti-ADAMTS13 antibodies in whom other treatments failed to limit the production of inhibitors, and suggests that re-treatment with rituximab should be considered when ADAMTS13 activity decreases and inhibitors reappear into the circulation, to avoid a new relapse.",
keywords = "ADAMTS13, Autoantibodies, Rare diseases, Rituximab, TTP",
author = "Elena Bresin and Sara Gastoldi and Erica Daina and Daniela Belotti and Enrico Pogliani and Paolo Perseghin and Scalzulli, {Potito R.} and Rossella Paolini and Raimondo Marcen{\`o} and Giuseppe Remuzzi and Miriam Galbusera",
year = "2009",
month = "2",
doi = "10.1160/TH07-12-0753",
language = "English",
volume = "101",
pages = "233--238",
journal = "Thrombosis and Haemostasis",
issn = "0340-6245",
publisher = "Schattauer GmbH",
number = "2",

}

TY - JOUR

T1 - Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies

AU - Bresin, Elena

AU - Gastoldi, Sara

AU - Daina, Erica

AU - Belotti, Daniela

AU - Pogliani, Enrico

AU - Perseghin, Paolo

AU - Scalzulli, Potito R.

AU - Paolini, Rossella

AU - Marcenò, Raimondo

AU - Remuzzi, Giuseppe

AU - Galbusera, Miriam

PY - 2009/2

Y1 - 2009/2

N2 - Thrombotic thrombocytopenic purpura (TTP) is a rare and severe disease characterized by thrombocytopenia, microangiopathic haemolytic anemia, neurological and renal involvement associated with deficiency of the von Willebrand factor-cleaving protease, ADAMTS13. Persistence of high titers of anti-ADAMTS13 autoantibodies predisposes to relapsing TTP. Since relapses are associated with high morbidity and mortality rates, the optimal therapeutic option should be a pre-emptive treatment able to deplete anti-ADAMTS13 autoantibodies and avoid relapses. Five patients who presented with persistence of undetectable ADAMTS13 activity and high titers of autoantibodies, were treated with rituximab as pre-emptive therapy during remission. Four of them were affected by relapsing TTP and one was treated after the first episode. ADAMTS13 activity ranging from 15% to 75% with disappearance of inhibitors was achieved after three months in all patients, and persisted >20% without inhibitors at six months. In three patients disease-free status is still ongoing after 29, 24 and six months, respectively. Relapses were documented in two patients during follow-up: in one patient remission lasted 51 months; while in the other patient relapse occurred after 13 months. Results demonstrated that rituximab used as pre-emptive treatment may be effective in maintaining a sustained remission in patients with anti-ADAMTS13 antibodies in whom other treatments failed to limit the production of inhibitors, and suggests that re-treatment with rituximab should be considered when ADAMTS13 activity decreases and inhibitors reappear into the circulation, to avoid a new relapse.

AB - Thrombotic thrombocytopenic purpura (TTP) is a rare and severe disease characterized by thrombocytopenia, microangiopathic haemolytic anemia, neurological and renal involvement associated with deficiency of the von Willebrand factor-cleaving protease, ADAMTS13. Persistence of high titers of anti-ADAMTS13 autoantibodies predisposes to relapsing TTP. Since relapses are associated with high morbidity and mortality rates, the optimal therapeutic option should be a pre-emptive treatment able to deplete anti-ADAMTS13 autoantibodies and avoid relapses. Five patients who presented with persistence of undetectable ADAMTS13 activity and high titers of autoantibodies, were treated with rituximab as pre-emptive therapy during remission. Four of them were affected by relapsing TTP and one was treated after the first episode. ADAMTS13 activity ranging from 15% to 75% with disappearance of inhibitors was achieved after three months in all patients, and persisted >20% without inhibitors at six months. In three patients disease-free status is still ongoing after 29, 24 and six months, respectively. Relapses were documented in two patients during follow-up: in one patient remission lasted 51 months; while in the other patient relapse occurred after 13 months. Results demonstrated that rituximab used as pre-emptive treatment may be effective in maintaining a sustained remission in patients with anti-ADAMTS13 antibodies in whom other treatments failed to limit the production of inhibitors, and suggests that re-treatment with rituximab should be considered when ADAMTS13 activity decreases and inhibitors reappear into the circulation, to avoid a new relapse.

KW - ADAMTS13

KW - Autoantibodies

KW - Rare diseases

KW - Rituximab

KW - TTP

UR - http://www.scopus.com/inward/record.url?scp=62449105955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62449105955&partnerID=8YFLogxK

U2 - 10.1160/TH07-12-0753

DO - 10.1160/TH07-12-0753

M3 - Article

C2 - 19190804

AN - SCOPUS:62449105955

VL - 101

SP - 233

EP - 238

JO - Thrombosis and Haemostasis

JF - Thrombosis and Haemostasis

SN - 0340-6245

IS - 2

ER -